U.S. market Closed. Opens in 7 hours 37 minutes

SRGA | Surgalign Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.1780 - 0.2380
52 Week Range 0.1780 - 0.2380
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 8,716,752
Average Volume N/A
Shares Outstanding 9,183,450
Market Cap 1,679,653
Sector Healthcare
Industry Medical - Devices
IPO Date 2000-08-11
Valuation
Profitability
Growth
Health
P/E Ratio -0.02
Forward P/E Ratio N/A
EPS -8.12
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 217
Country USA
Website SRGA
Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops Augmented Reality and Artificial Intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois.
SRGA's peers: ICAD
*Chart delayed
Analyzing fundamentals for SRGA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see SRGA Fundamentals page.

Watching at SRGA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SRGA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙